key: cord-1044214-2rj15rjv
authors: Woodcock, R. A.; Bartels, L. J.
title: Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms
date: 2022-02-24
journal: nan
DOI: 10.1101/2022.02.23.22271144
sha: dfd0226a93a1d81634e26bf3dfa3aff3cbd4ea84
doc_id: 1044214
cord_uid: 2rj15rjv

Hypothesis: This study investigates whether U.S. Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System (VAERS) data suggest an association between vertigo, tinnitus, hearing loss, Bell's palsy and the COVID-19 vaccines administered in the United States. Background: Published case reports suggest a possible association between various otologic symptoms and the COVID-19 vaccines, but the only published analysis of VAERS data, which did not account for underreporting of late-appearing adverse events, found no association between hearing loss and the vaccines. Methods: The incidence in VAERS of vertigo, tinnitus, hearing loss, and Bell's palsy associated with COVID-19 vaccinations administered between December 14, 2020 and June 7, 2021 was compared with published rates for the general population. To account for underreporting of late-appearing adverse events, incidences were calculated using only the initial part of the observation period, during which reported events spike above expected events. Results: The COVID-19 vaccines were associated with statistically significant increases in the incidence of vertigo, tinnitus, hearing loss, and Bell's palsy of 1877, 50, 12, and 14 cases per 100,000, respectively. In relation to the mRNA-1273 or BNT162b2 vaccines, the Ad26.COV2.S vaccine was associated with a statistically significant excess incidence of vertigo, tinnitus, and hearing loss of at least 723, 57, and 55 cases per 100,000, respectively. Conclusion: These results suggest an association between the COVID-19 vaccines and vertigo, tinnitus, hearing loss, and Bell's palsy. They also suggest that, with respect to vertigo, tinnitus, and hearing loss, the association is relatively strong for the Ad26.COV2.S vaccine.

Published case reports suggest a possible association between the COVID-19 vaccines and 24 various otologic symptoms, including hearing loss, tinnitus, and vertigo. 1-3 However, the only 25 preliminary study of otologic symptoms in U.S. Centers for Disease Control and Prevention 26

Vaccine Adverse Event Reporting System (VAERS) data published to date, in which Formeister 27 et al. investigated reports of hearing loss, failed to find an association. 4, 5 This may be because 28 vaccine adverse event reports relate to a single trigger-vaccination-whereas the population 29 incidence rates to which they must be compared relate to multiple triggers. 6 For example, the 30 population incidence of vertigo includes cases of vertigo due to trauma, viral infection, and genetic 31 disorders, among other things, whereas doctors and patients likely tend to report to VAERS only 32 cases of vertigo that they believe to be triggered by vaccination. As a result, the incidence rate of 33 vertigo in the VAERS reports will be lower than the population incidence rate unless vaccination 34 triggers more vertigo than all other triggers combined. 35

The U.S. Centers for Disease Control and Prevention (CDC) tries to address this problem by 36 encouraging doctors and patients to report all symptoms they encounter after vaccination. 7 In 37 theory, that should ensure that symptoms due to all triggers, including vaccination, are reported, 38

with the result that, if vaccination triggers additional cases of a particular symptom, then the 39 incidence rate in the VAERS reports will be higher than the population incidence rate and 40 researchers will be able to infer from this difference that there is an association between the 41 symptom and vaccination. 42

Unfortunately, doctors and patients do not heed the CDC. As Figure 1 shows, VAERS reports 43 for all vaccines, COVID or otherwise, decline dramatically as the date of onset of the reported 44

If the number of cases reported during the peak reporting period immediately after vaccination-67 the "spike period"-exceeds the number of cases expected during that period based on the 68 population incidence rate of the symptom, then it follows that the vaccine is a trigger of the 69 symptom, even if reported cases fall below expected cases for the rest of the observation period, 70 and even if the incidence rate implied by the reports, if calculated over the entire observation 71 period, is below the population incidence rate. For the only way in which reported cases can 72 exceed expected cases during any part of an observation period, despite underreporting of cases 73 due to non-vaccine triggers, is if vaccine-triggered cases of the symptom are numerous enough 74 over that period to make up the difference. But the existence of any number of vaccine-triggered 75 cases, if statistically significant in magnitude, is sufficient to establish an association between the 76 vaccine and the symptom. 77

Consider a numerical illustration. Suppose that vaccination triggers one hundred excess cases 78 of vertigo in the first day after vaccination and none on the second day, and that all other triggers 79 cause an additional hundred cases every day, but that doctors and patients, despite reporting all 80 symptoms on the first day regardless of trigger, report none on the second day, because they 81 assume that none of the day-two symptoms are triggered by the vaccine. If 365,000,000 82 vaccinations are observed, then for a 2-day observation period, the incidence of vertigo is 10 (per 83 100,000 person-years, as with all incidence rates discussed in the present study), but the population 84 incidence (which is based on the number of cases caused by all other triggers) is 15, suggesting, 85 falsely, that there is no association between vaccination and the symptom. If, however, one 86 considers only the first day, during which total reported cases of 200 spike above expected cases 87 of 100, then the incidence is 20, which exceeds the population incidence of 15 and therefore 88 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 COVID-19 Vaccines and Otologic Symptoms 5 correctly indicates the existence of an association. 89

An additional consideration complicates analysis of spike periods: reports may not be 90 accurate. As a result, the presence of a spike in raw report numbers for a particular symptom is 91 not sufficient to suggest the existence of an association between the vaccine and the symptom. 92

The spike must be discounted, either through examination of individual reports or by a rate of 93 accuracy derived from analysis of past reports. Even if discounting eliminates the spike, however, 94 the analysis does not end, because the studies, such as that of Miller et al., that provide sensitivity 95 rates for reporting of adverse events with onset close to the date of vaccination are likely to capture 96 underreporting during spike periods even if they do not capture underreporting of cases 97 thereafter. 9 The same is true for sensitivity rates extrapolated from a comparison with clinical trial 98

reports. Published sensitivity rates and those extrapolated from clinical trials can therefore be used 99 to offset the accuracy discount with a multiplier that accounts for underreporting during the spike. 100

To investigate the relationship between the COVID vaccines administered in the United States 102 (Moderna's mRNA-1273, Pfizer-BioNTech's BNT162b2, and Johnson & Johnson's 103 Ad26.COV2.S) and otologic symptoms, analysis of spikes in reports to VAERS of vertigo, 104 tinnitus, hearing loss, and Bell's palsy over expected levels were carried out. To avoid bias 105 associated with the ongoing arrival of new reports regarding the COVID-19 vaccines, the analysis 106 was limited to vaccines administered between December 14, 2020 and June 7, 2021, to symptoms 107 with an onset within 30 days of vaccination, and to reports made within 60 days of vaccination. 108

The MedDRA-coded symptom fields in the VAERS database were searched for "vertigo," 109 "tinnitus," "hearing loss," "bell's palsy," and synonyms, and the results filtered for the 110 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint "COVID19" vaccine type to create datasets for each symptom. A much lower sensitivity rate-0.6%, corresponding to a multiplier of 166.9-was used for 128 vertigo, because, as Neuhauser has pointed out, vertigo is common in the general population, 129 affecting between 20% and 30% of adults. 11 Doctors and patients may therefore be less likely to 130 report vertigo in connection with the COVID-19 vaccines than they are to report tinnitus, hearing 131 loss, or Bell's palsy, each of which is rare in comparison. 11 To identify an appropriate reporting 132 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint

7 sensitivity rate for vertigo, the incidence of other common symptoms-pain, erythema, swelling, 133 fever, headache, fatigue, myalgia, and nausea or vomiting-reported in the COVID-19 vaccines' 134 Phase III clinical trials was compared with the incidence of the same symptoms in the VAERS 135 reports and the largest result-that for fever-was used to obtain the 0.6% reporting sensitivity 136 rate. 12-14 A comparison with clinical trial reports was considered probative of the true reporting 137 sensitivity rate during the spike period because clinical trial administrators solicit reports from 138 trial subjects within seven days of vaccination. 12-14 139

Spike periods were determined after application of the 8% accuracy discount and the 140 applicable underreporting multiplier to the VAERS report counts for each symptom. As shown in 141 Figure 3 and discussed more fully in the Results section, the spike period was two days each for 142 vertigo, tinnitus, and Bell's palsy, and one day for hearing loss. The statistical significance of the 143 incidence rate of each symptom over its spike period, in relation to the published population 144 incidence rate for the symptom, was determined using the normal approximation to the binomial 145 distribution for one-sample inference with two tails. 15-18 146

The proportional reporting ratio (PRR), 19 which compares the incidence rate of symptoms in 147 reports related to the vaccine at issue (here, the COVID-19 vaccines) to the rate of all other 148 symptoms in all other VAERS reports, 20 was also calculated for all four symptoms. The PRR has 149 two helpful features. First, it compares VAERS data with other VAERS data, so the problem of 150 comparing single-trigger VAERS incidence rates to multiple-trigger population incidence rates is 151 avoided. Second, the PRR provides a useful check on the appropriateness of the accuracy and 152

reporting sensitivity rates used in the present study, because, if accuracy and reporting sensitivity 153 rates are constant across all vaccines, then these rates cancel out of the PRR, making the PRR 154 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint

8 invariant in reporting accuracy and sensitivity assumptions. The statistical significance of the 155 PRRs, in relation to the null hypothesis of one (i.e. that there is no difference between the 156 incidence of the symptom in COVID-19 vaccine reports and the incidence of all other symptoms 157 in all other vaccine reports) was determined using the chi-squared test with one degree of freedom. 158

Finally, to investigate the relative association of different COVID-19 vaccines with vertigo, 159 tinnitus, hearing loss, and Bell's palsy, VAERS spike-period case counts, discounted as above, 160

were categorized by vaccine manufacturer, incidence rates for each were calculated using CDC 161 data on total administered vaccine doses per manufacturer, and, for each symptom, the normal 162 approximation to the binomial distribution for two-sample inference was applied with two tails. 163

For all three tests, p-values below 0.05 were considered significant. 164

University of Kentucky determined that this study is exempt from institutional review board 165 approval because the study uses deidentified data publicly available on the CDC website. 166 III. RESULTS 167 Figure 3 shows the distribution of cases, after adjustment for accuracy and underreporting, in 168 terms of time to symptom onset, including the spike period for each symptom. The incidence rate 169 of vertigo in the VAERS reports over vertigo's two-day spike period was 3,277 (per 100,000 170 person-years, as for all incidence rates reported here), significantly in excess of the population 171 The incidence rate of hearing loss in the VAERS reports over hearing loss's one-day spike period 175 was 39, significantly in excess of the population incidence of hearing loss of 27 reported by 176 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint

Alexander et al. (p < 0.00001). 18 The incidence rate of Bell's palsy in the VAERS reports over 177

Bell's palsy's two-day spike period was 37, significantly in excess of 23, which is the average of 178 the population incidence rates for Bell's palsy referenced by Ozonoff et al. (p < 0.00001). 15 As 179 Table 2 , which reports these results, shows, incidence rates calculated using the three-week 180 observation period employed by Formeister et al., rather than the spike periods, were, by contrast, 181 all lower than their respective population incidence rates, by 846 for vertigo, 36 for tinnitus, 22 182 for hearing loss, and 14 for Bell's palsy. Incidence rates in the VAERS reports break even with 183 population incidence rates at approximately a one-week observation period. 184

The results for vertigo and tinnitus were robust to lower underreporting multipliers. As Table  185 2 also reports, a statistically significant excess incidence of tinnitus remained after reduction of 186 the underreporting multiplier from 3.3 to the value of 2 used by Formeister et al., and a statistically 187 significant excess incidence of vertigo remained after the underreporting multiplier was scaled 188 down in the same proportion (i.e., by the ratio of 2 to 3.3). 189

The PRRs, which require no assumption regarding the rate of accuracy or the rate of reporting 190 sensitivity, were, for vertigo, tinnitus, hearing loss, and Bell's palsy, 4. 76, 5.41, 2.63, and 1.46, 191 respectively, as shown in Table 3 . Those for vertigo and tinnitus exceeded the null hypothesis of 192 one to a statistically significant degree (p < 0.001 for vertigo and p < 0.0001 for tinnitus). This 193 result was consistent with the robustness of the spike period results for vertigo and tinnitus. 194

These results were clinically significant. As Table 2 shows, over the course of the two-day 195 spike period after vaccination, 30,761 of the 171 million people who received at least one dose of 196 vaccine in the United States during the study period (about 1 per 5,569 persons receiving at least 197 one dose) are estimated to have had vertigo. That was 17,619 more cases than the 13,142 cases 198 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint that were expected over that period based on the population incidence of vertigo (an excess rate 199 of 1 per 9,723 persons receiving at least one dose). For tinnitus, the excess of reported cases over 200 expected cases over the two-day tinnitus spike period was 466 (an excess rate of 1 per 367,579 201 persons receiving at least one dose). For hearing loss, it was 58 excess cases over the one-day 202 hearing loss spike period (about 1 per 2.94 million persons receiving at least one dose), and for 203

Bell's palsy it was 130 excess cases over the two-day Bell's palsy spike period (about 1 extra 204

Bell's palsy case per 1.32 million persons receiving at least one dose). 205 Table 4 sets forth the results regarding the relative associations of the three vaccines 206 administered in the United States. The incidence of vertigo associated with the Ad26.COV2.S 207 vaccine in the VAERS reports was 4,258, in excess of the incidence of 3,535 associated with the 208 mRNA-1273 vaccine and the incidence of 2,947 associated with the BNT162b2 vaccine. The 209 excess in the incidence of vertigo associated with the Ad26.COV2.S vaccine in relation to both 210 the mRNA-1273 vaccine and the BNT162b2 vaccine was statistically significant (p < 0.00001), 211 as was the excess in the incidence of vertigo associated with the mRNA-1273 vaccine in relation 212 to the BNT162b2 vaccine (p < 0.00001). The incidence of tinnitus associated with the 213 Ad26.COV2.S vaccine in the VAERS reports was 157, in excess of the incidence of 100 associated 214 with both the mRNA-1273 and BNT162b2 vaccines to a statistically significant degree (p < 0.001 215 and p<0.0001, respectively). The incidence of hearing loss associated with the Ad26.COV2.S 216 vaccine in the VAERS reports was 93, in excess of the incidences associated with the mRNA-217 1273 and BNT162b2 vaccines of 33 and 37, respectively, to a statistically significant degree (p < 218 0.00001 and p < 0.0001, respectively). The incidence of Bell's palsy associated with the 219 BNT162b2 and mRNA-1273 vaccines in the VAERS reports was 37 for both, which exceeded the 220 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint incidence of 36 associated with the Ad26.COV2.S vaccine, but not to a statistically significant 221 degree. 222

These results were also clinically significant. The comparatively higher vertigo incidence rate 223 of the Ad26.COV2.S vaccine implies that, had the 171 million people who received at least one 224 vaccine dose over the study period all received the Ad26.COV2.S vaccine, rather than one of the 225 assortment of Ad26.COV2.S, BNT162b2, and mRNA-1273 vaccines that was actually 226 administered, there would have been 39,970 cases of vertigo over the two-day spike period, 9,209 227 more than the 30,761 cases estimated to have actually occurred (an excess rate of about 1 per 228 18,602 persons receiving at least one dose). Similarly, the vertigo incidence rate of the mRNA-229 1273 vaccine, which was elevated relative to the vertigo incidence rate of the BNT162b2 vaccine, 230 implies that, had mRNA-1273 alone been administered, there would have been 33,183 cases of 231 vertigo over the two-day spike period, 2,422 more than the 30,761 cases estimated to have actually 232 occurred (an excess rate of about 1 per 70,733 persons receiving at least one dose). The 233 comparatively higher tinnitus incidence rate of the Ad26.COV2.S vaccine implies that, had 234 Ad26.COV2.S alone been administered, there would have been 1,471 cases of tinnitus over the 235 two-day spike period, 498 more than the 973 cases estimated to have actually occurred (an excess 236 rate of 1 per 344,028 persons receiving at least one dose). Finally, the comparatively higher 237 hearing loss incidence rate of the Ad26.COV2.S vaccine implies that, had Ad26.COV2.S alone 238 been administered, there would have been 435 cases of hearing loss over the one-day spike period, 239 250 more than the 185 cases estimated to have actually occurred (an excess rate of 1 per 684,947 240 persons receiving at least one dose). 241 IV. DISCUSSION 242 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271144 doi: medRxiv preprint These results suggest a statistically significant association between the COVID-19 vaccines 243 and otologic symptoms, particularly vertigo and tinnitus, during the one-to-two-day immediate 244 post-vaccination periods over which reported cases for these symptoms spike above expected 245 cases. The results contrast with results obtained by including cases with later onset in the 246 observation period, such as those published by Formeister et al. The results also suggest that the 247 Ad26.COV2.S vaccine is more likely to trigger vertigo, tinnitus, or hearing loss than are the 248 mRNA-1273 or BNT162b2 vaccines. The number of excess cases of vertigo, tinnitus, hearing loss, 249 and Bell's palsy associated with the vaccines is quite small relative to the total number of people 250 who have received a dose of the vaccines, particularly in the case of tinnitus, hearing loss, and 251

Bell's palsy, but still clinically significant. The existence of an association over the one-to-two-252 day spike periods does not exclude the existence of an association between the vaccines and 253 symptoms with later onset. Underreporting to VAERS prevents verification of such an association, 254 however. 255

More investigation is required to confirm these associations, because the true accuracy and 256 underreporting sensitivity rates are unknown. One reason for which the 30% sensitivity rate 257 applied for tinnitus, hearing loss, and Bell's palsy might be incorrect is that media attention paid 258 to the COVID-19 vaccines may have pushed their reporting sensitivity rates above those of the 259 vaccines considered by Miller et al., upon which the 30% rate is based. 9,21 More investigation is 260 also required to determine the extent of recovery from the symptoms considered in the present 261 study, either to tolerability or to complete resolution, especially as there are reports of 262 improvement for some symptoms. 2,3 263 V. CONCLUSION 264 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 This study created a novel way to compare the incidence of post-vaccine symptoms to 265 published population incidence rates by using only cases with onset in the immediate one-to-two-266 day post-vaccination periods during which reported cases spike above expected cases to calculate 267 incidence rates. In looking at VAERS reports of vertigo, tinnitus, hearing loss, and Bell's palsy in 268 recipients of COVID-19 vaccines, statistical evidence of an association of the vaccines with an 269 excess of these cases appears at rates ranging from about 1 excess case per 5,500 vaccinated 270 persons to about 1 excess case per 2.94 million vaccinated persons. Variations of this methodology 271 might be helpful in investigating the risks of other vaccines. 272

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 which the spike of reported cases above expected cases ends. The vertical axis is labeled in report 345 numbers and the horizontal access is labeled in the number of days between administration of the 346 dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an 347 underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case 348 counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts. 349 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Tables for "Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms"

1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10. 1101 /2022 Tables for "Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms" 2 No spike period; reported cases never exceed expected cases, suggesting the absence of a positive association between hearing loss and the COVID-19 vaccines. Incidence over a 21-day observation period is 3.21 per 100,000 person-years.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10. 1101 /2022 Tables for "Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms"

3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. 

The solid line shows the number of cases reported and the horizontal dashed line shows the expected number of cases based on the population incidence rate. The vertical dotted line shows the number of days after dose administration at which the spike of reported cases above expected cases ends. The vertical axis is labeled in report numbers and the horizontal access is labeled in the number of days between administration of the dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts. 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Relative Incidence of Vertigo, Tinnitus, Hearing Loss, and Bell's Palsy Associated with the mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines